1. Home
  2. MRCY vs ACAD Comparison

MRCY vs ACAD Comparison

Compare MRCY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRCY
  • ACAD
  • Stock Information
  • Founded
  • MRCY 1981
  • ACAD 1993
  • Country
  • MRCY United States
  • ACAD United States
  • Employees
  • MRCY N/A
  • ACAD N/A
  • Industry
  • MRCY
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRCY
  • ACAD Health Care
  • Exchange
  • MRCY Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • MRCY 4.6B
  • ACAD 3.9B
  • IPO Year
  • MRCY 1998
  • ACAD 2004
  • Fundamental
  • Price
  • MRCY $70.17
  • ACAD $25.17
  • Analyst Decision
  • MRCY Buy
  • ACAD Buy
  • Analyst Count
  • MRCY 7
  • ACAD 21
  • Target Price
  • MRCY $76.43
  • ACAD $29.00
  • AVG Volume (30 Days)
  • MRCY 639.3K
  • ACAD 1.6M
  • Earning Date
  • MRCY 11-04-2025
  • ACAD 11-05-2025
  • Dividend Yield
  • MRCY N/A
  • ACAD N/A
  • EPS Growth
  • MRCY N/A
  • ACAD 98.53
  • EPS
  • MRCY N/A
  • ACAD 1.54
  • Revenue
  • MRCY $932,798,000.00
  • ACAD $1,047,118,000.00
  • Revenue This Year
  • MRCY $6.17
  • ACAD $14.12
  • Revenue Next Year
  • MRCY $8.23
  • ACAD $11.80
  • P/E Ratio
  • MRCY N/A
  • ACAD $15.82
  • Revenue Growth
  • MRCY 8.63
  • ACAD 12.69
  • 52 Week Low
  • MRCY $37.28
  • ACAD $13.40
  • 52 Week High
  • MRCY $85.33
  • ACAD $26.65
  • Technical
  • Relative Strength Index (RSI)
  • MRCY 44.78
  • ACAD 66.30
  • Support Level
  • MRCY $65.04
  • ACAD $22.81
  • Resistance Level
  • MRCY $70.89
  • ACAD $23.98
  • Average True Range (ATR)
  • MRCY 2.65
  • ACAD 0.97
  • MACD
  • MRCY -0.26
  • ACAD 0.15
  • Stochastic Oscillator
  • MRCY 45.25
  • ACAD 100.00

About MRCY Mercury Systems Inc

Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: